Drug Type Monoclonal antibody |
Synonyms Recombinant humanized anti-PD-1 monoclonal antibody(Taizhou Hanzhong Biomedical Co., Ltd.), 重组人源化抗PD-1单抗(泰州翰中生物), AK-103 + [3] |
Target |
Action inhibitors |
Mechanism PD-1 inhibitors(Programmed cell death protein 1 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Inactive Organization- |
License Organization |
Drug Highest PhaseApproved |
First Approval Date China (19 Jul 2022), |
RegulationBreakthrough Therapy (China), Conditional marketing approval (China) |


| Indication | Country/Location | Organization | Date |
|---|---|---|---|
| Melanoma | China | 20 Sep 2022 | |
| MSI-H/dMMR Solid Tumors | China | 19 Jul 2022 |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Nasopharyngeal Carcinoma | Phase 3 | China | 06 May 2025 | |
| Metastatic Colorectal Carcinoma | Phase 3 | China | 28 Feb 2023 | |
| Microsatellite instability-high colorectal cancer | Phase 3 | China | 28 Feb 2023 | |
| Microsatellite instability-high colorectal cancer | Phase 3 | China | 28 Feb 2023 | |
| Embolism | Phase 3 | China | 03 Feb 2023 | |
| Embolism | Phase 3 | China | 03 Feb 2023 | |
| Metastatic melanoma | Phase 3 | China | 31 Dec 2022 | |
| Gastroesophageal junction adenocarcinoma | Phase 3 | China | 25 Mar 2022 | |
| stomach adenocarcinoma | Phase 3 | China | 25 Mar 2022 | |
| Metastatic Non-Squamous Non-Small Cell Lung Carcinoma | Phase 3 | China | 25 Sep 2020 |
Phase 2 | 49 | cdzgsyvejt(mbtoieuowf) = One death occurred in Arm B (post-gastrostomy, after 1 cycle ADC), deemed unrelated to study treatment. mnhkclbwyb (ggzlvgglsm ) View more | Positive | 23 Oct 2026 | |||
Phase 2 | EGFR positive Neoplasms EGFR-positive | 30 | bjjlkfksmo(sctnqftfdc) = djvrxjlwco fadqegftxm (kkgpdptepc, 26.7 - 62.9) View more | Positive | 23 Oct 2026 | ||
(BRAF mutant) | bjjlkfksmo(sctnqftfdc) = lmouflxlsu fadqegftxm (kkgpdptepc, 24.8 - 69.9) | ||||||
Phase 1/2 | Nasopharyngeal Cancer, Recurrent EGFR-positive | 31 | kuoimcnlwx(rbutkrwrmq) = fvfvamtayg bhbmrlkbla (helofazggp, 52.0 - 85.8) View more | Positive | 01 Oct 2026 | ||
Phase 1/2 | Rhabdomyosarcoma Neoadjuvant | 42 | (intermediate or high-risk rhabdomyosarcoma) | gpizndoxoi(sdhdnpkrnl) = fngfmozris rvqlohcldh (bbkybtebqq ) View more | Positive | 21 Apr 2026 | |
Phase 2 | 37 | kqizkvwxrs(znydxjggqt) = hrstlduuzt bqxdkegjsr (zixprvvplk ) View more | Positive | 17 Oct 2025 | |||
kqizkvwxrs(znydxjggqt) = flcumkutdb bqxdkegjsr (zixprvvplk ) View more | |||||||
Phase 2 | Nasopharyngeal Cancer, Recurrent Second line | 30 | otchrpipuc(tijfsfnhnl) = fizoyybvgn lpinjljika (hjsdfstsqb ) View more | Positive | 17 Oct 2025 | ||
Phase 1/2 | Childhood Rhabdomyosarcoma Neoadjuvant | 15 | Pucotenlimab + Standard Chemotherapy | guxogcngry(lvmeoppbiq) = ijviecbzjw tjgfcyaeng (ejcmmgnpjw ) View more | Positive | 30 May 2025 | |
Phase 2 | 100 | adpdstzarz(eqmleaegkv) = tmkipqpror ucwkivfber (xshmodwqmw, 39.8 - 60.2) View more | Positive | 30 May 2025 | |||
Phase 2 | 30 | uxolmycody(iogtlzlzid) = eihkoeswfm qamnphfjow (vtbxfiyfwp, 59.7 - 73.7) View more | Positive | 07 Dec 2024 | |||
Phase 1 | 20 | Axitinib + anti–PD-1 ab (Pucotenlimab) + Oncolytic virus (OH2) | kizfunheqi(cqwthzxjwo) = uqzsbmckze hjvskygpxy (chsbzsacsg ) View more | Positive | 25 Sep 2024 |






